TGTX: Bullish thesis on TG Therapeutics, Inc.

What happened: TG Therapeutics, Inc. (TGTX) saw its share price rise following positive results from its key drug, Ublituximab. ClearBridge Investments, a global equity manager, highlighted TGTX as a top performer in their SMID Cap Growth Strategy for Q2 2026. Additionally, TGTX initiated a Phase 2 clinical trial for its drug Briumvi in adults with treatment-resistant schizophrenia on July 6, 2026.

Market impact: The biotechnology sector, particularly companies focused on immunology and neuroscience, has been positively affected. TGTX's strong performance has driven investor interest in the sector, with the Russell 2500 Growth Index experiencing a robust quarter. The company's valuation has also seen a repricing, with trailing and forward P/E ratios of 17.59 and 38.76, respectively.

What to watch next: Investors should monitor the upcoming Phase 2 data for Briumvi, expected in late 2027. Additionally, TGTX's earnings report for Q3 2026, scheduled for release in October, will provide insights into the company's financial health and pipeline progress. Lastly, regulatory decisions on Ublituximab's label expansion, anticipated in early 2027, could significantly impact TGTX's share price.